- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.11. | DIAGONAL BIO AB: Renowned horse race jockey and trainer conducts pilot test of LAMPlify® | 1 | Cision News | ||
| 18.11. | DIAGONAL BIO AB: Nomination Committee appointed for Diagonal Bio | 1 | Cision News | ||
| 13.11. | DIAGONAL BIO AB: Diagonal Bio announces pilot test with LAMPlify® at Kolgjini Stables | 1 | Cision News | ||
| DIAGONAL BIO Aktie jetzt für 0€ handeln | |||||
| 11.11. | Nasdaq Stockholm AB: Diagonal Bio AB receives observation status | 162 | GlobeNewswire | Today, on November 11, 2024, Diagonal Bio AB (the "Company") disclosed a press
release with information on the Company's financial situation.
The rules of Nasdaq First North Growth Market state that... ► Artikel lesen | |
| 11.11. | DIAGONAL BIO AB: Diagonal Bio announces that it is exploring financing options | 3 | Cision News | ||
| 31.10. | DIAGONAL BIO AB: Diagonal announces first pilot test at a stud with LAMPlify® | 4 | Cision News | ||
| 25.10. | DIAGONAL BIO AB: Diagonal Bio announces pilot test of LAMPlify® at Norwegian University of Life Sciences | 5 | Cision News | ||
| 22.10. | DIAGONAL BIO AB: Diagonal Bio will present LAMPlify® at a partnered event for trainers at Jägersro | 1 | Cision News | ||
| 11.10. | DIAGONAL BIO AB: Diagonal Bio announces successful external validation of LAMPlify® for viruses in pigs | 1 | Cision News | ||
| 08.10. | DIAGONAL BIO AB: Hunneberga Horse Stable to conduct pilot test of LAMPlify® | 2 | Cision News | ||
| 03.10. | DIAGONAL BIO AB: Horse trainer Daniel Redén at StallZet will conduct a pilot with LAMPlify® | 1 | Cision News | ||
| 02.10. | Diagonal Bio AB's warrant exercise registered at the Swedish Companies Registration Office | 2 | Cision News | ||
| 27.09. | Diagonal Bio AB announces the outcome of the exercise of warrants of series TO 1 | 1 | Cision News | ||
| 19.09. | DIAGONAL BIO AB: The last day of trading in warrants of series TO 1 is on the 24th of September 2024 | 2 | Cision News | ||
| 12.09. | DIAGONAL BIO AB: The exercise period for warrants of series TO 1 commences today | 1 | Cision News | ||
| 11.09. | DIAGONAL BIO AB: The exercise price for warrants of series TO 1 has been set to SEK 0,05 per new share | 1 | Cision News | ||
| 06.09. | DIAGONAL BIO AB: Diagonal Bio announces successful external validation of LAMPlify® for respiratory viruses in horses | 1 | Cision News | ||
| 21.08. | DIAGONAL BIO AB: Diagonal Bio receives order from the Technical University of Denmark | 2 | Cision News | ||
| 16.05. | Nasdaq Stockholm AB: New equity right for trading, Diagonal Bio AB TO1 | 223 | GlobeNewswire | At the request of Diagonal Bio AB, Diagonal Bio AB equity rights will be traded
on First North Growth Market as from May 17, 2024.
Security name: Diagonal Bio AB TO1
-----------------------------------
Short... ► Artikel lesen | |
| 08.05. | Nasdaq Stockholm AB: New last trading date in paid subscription units issued by Diagonal Bio AB | 238 | GlobeNewswire | At the request of Diagonal Bio AB, the last trading day in Diagonal Bio AB's
paid subscription shares will be changed on Nasdaq Stockholm from 10 May 2024
to 13 May 2024.
Short name: DIABIO... ► Artikel lesen |
Seite:
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| INTELLIA THERAPEUTICS | 11,760 | +0,38 % | Cathie Wood's ARK buys Intellia, sells Tesla in latest stock trades | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,881 | -0,17 % | Cathie Wood's ARK buys BEAM and PACB, sells IONS stock | ||
| CENTOGENE | 0,092 | -16,36 % | Centogene NV: CENTOGENE Announces Voting Results of Extraordinary General Meeting | CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 04, 2024 (GLOBE NEWSWIRE) -- Centogene N.V. (OTC: CNTGF) ("CENTOGENE" or the "Company"), the essential life science partner for data-driven answers... ► Artikel lesen | |
| ATAI LIFE SCIENCES | 1,210 | +4,72 % | ATAI Life Sciences N.V. - 10-Q/A, Quarterly Report | ||
| BIOMERIEUX | 100,90 | -1,08 % | Research and Markets: Europe Companion Diagnostics Market Analysis and Forecast, 2023-2033 with Competitive Analysis of Key Players - bioMerieux, F. Hoffmann-La Roche, ICON, and QIAGEN - ResearchAndMarkets.com | The "Europe Companion Diagnostics Market: Focus on Application, End User, Technology, and Country Analysis and Forecast, 2023-2033" report has been added to ResearchAndMarkets.com's offering.
The... ► Artikel lesen | |
| CYCLACEL | 0,300 | 0,00 % | Cyclacel stock plunges to 52-week low, hits $0.32 | ||
| SYROS PHARMACEUTICALS | 0,210 | +5,53 % | Kia Syros: Wird aus dem kleinen Verbrenner der EV1? | ||
| GENUS | 17,800 | -2,20 % | Genus Plc Expects FY25 Group Adj Profit Before Tax To Be In-line With Market View | LONDON (dpa-AFX) - Global animal genetics company Genus (GNS.L), on Tuesday, issued a trading update for the four months ending 31 October 2024 and said the Board expects Group adjusted profit... ► Artikel lesen | |
| XTL BIOPHARMACEUTICALS | 1,330 | 0,00 % | XTL BIOPHARMACEUTICALS LTD - 6-K, Report of foreign issuer | ||
| ANAPTYSBIO | 13,800 | -1,43 % | Deep Dive Into AnaptysBio Stock: Analyst Perspectives (9 Ratings) | ||
| ABIONYX PHARMA | 1,180 | -0,17 % | ABIONYX Pharma: Monthly Statement of Total Voting Rights and Shares Forming the Company's Share Capital | Article L233-8-II of the French Commercial Code
Article 223-16 of the General Regulations of the AMF (French Financial Markets Authority)
Regulatory News:
ABIONYX Pharma (Paris:ABNX):
Market:... ► Artikel lesen | |
| MEIRAGTX | 5,550 | +0,91 % | 392,400 Shares in MeiraGTx Holdings plc (NASDAQ:MGTX) Purchased by Garden State Investment Advisory Services LLC | ||
| METABOLIC EXPLORER | 0,000 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 09.10.2024 | The following instruments on Boerse Frankfurt do have their last trading day on 09.10.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 09.10.2024ISIN NameAU0000064966 VIRG.MON.... ► Artikel lesen | |
| AKESO | 7,500 | -0,66 % | Akeso, Inc.: Akeso Announces First Patient Enrollment in Phase 3 Trial of Ivonescimab Combination as First-Line Therapy for Biliary Tract Tumors, Compared to Durvalumab | HONG KONG, Oct. 31, 2024 /PRNewswire/ -- Akeso Biopharma (9926.HK) is pleased to announce the successful enrollment of the first patient in the HARMONi-GI-01/AK112-309... ► Artikel lesen | |
| ISOFOL MEDICAL | 0,205 | +0,24 % | Isofol Medical AB: Isofol Medical AB (publ) publishes interim report, January-September 2024 | GOTHENBURG, Sweden, November 12, 2024 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company's interim report for January-September 2024 is now available, in Swedish... ► Artikel lesen |
Das Unternehmen DIAGONAL BIO AB kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell +5,26 % bei einem Aktienkurs von 0,002 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGONAL BIO AB finden Sie auf Wallstreet Online.
